RI RenovoRx, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the RenovoRx, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, RenovoRx, Inc. has published 37 reports. Market capitalisation: €43.5m. The latest transaction was reported on 7 April 2026 (Attribution). Among the most active insiders: Agah Ramtin. The full history is accessible without an account.
€190,707
30 ops.
Buy Volume
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,826 of 29,064 companies
FCF yld -25%
Earn yld -26%
EV/EBITDA ·
ROE -100%
Gross mgn 71%
Net mgn ·
Debt/EBITDA ·
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 April 2026
All Executives37 Thresholds0 Prospectus0 Other0
Declarations 37 total
◆ Chief Financial Officer · Executives · 3 Apr 2026
80,000 shares 0Common Stock SEC:0001493152-26-015593:0
◆ Chief Financial Officer · Executives · 25 Mar 2026
12,380 shares 0Common Stock SEC:0001493152-26-013083:0
▲ Chief Executive Officer · Executives · 20 Mar 2026
24,300 shares Common Stock SEC:0001493152-26-012482:0
Canonical exit: 18 Jun 2026 (T+90) ▲ Director · Executives · 20 Mar 2026
9,720 shares Common Stock SEC:0001493152-26-012483:0
Canonical exit: 18 Jun 2026 (T+90) ▲ Chief Financial Officer · Executives · 20 Mar 2026
97,200 shares Common Stock SEC:0001493152-26-012481:0
Canonical exit: 18 Jun 2026 (T+90) ▲ Chief Medical Officer · Executives · 21 Jan 2026
10,000 shares @ US$0.9975 6.4% of flow Common Stock SEC:0001493152-26-003181:0
Canonical exit: 21 Apr 2026 (T+90) ▲ Chief Medical Officer · Executives · 31 Dec 2025
9,795 shares @ US$0.86 5.4% of flow Common Stock SEC:0001493152-26-000255:0
Canonical exit: 31 Mar 2026 (T+90) ▲ Chief Medical Officer · Executives · 30 Dec 2025
205 shares @ US$0.826 0.1% of flow Common Stock SEC:0001493152-26-000157:0
Canonical exit: 30 Mar 2026 (T+90) ▲ Chief Executive Officer · Executives · 18 Dec 2025
5,000 shares @ US$0.9013 8.1% of flow Common Stock SEC:0001493152-25-028650:0
Canonical exit: 18 Mar 2026 (T+90) ▲ Chief Executive Officer · Executives · 17 Dec 2025
5,000 shares @ US$0.8524 8.3% of flow Common Stock SEC:0001493152-25-028439:0
Canonical exit: 17 Mar 2026 (T+90) ▲ Chief Medical Officer · Executives · 16 Dec 2025
12,000 shares @ US$0.85 7.4% of flow Common Stock SEC:0001493152-25-028057:0
Canonical exit: 16 Mar 2026 (T+90) ▲ Chief Medical Officer · Executives · 5 Dec 2025
10,000 shares @ US$0.96 7.6% of flow Common Stock SEC:0001493152-25-026516:0
Canonical exit: 5 Mar 2026 (T+90) ▲ Chief Medical Officer · Executives · 21 Nov 2025
10,000 shares @ US$0.80 6.9% of flow Common Stock SEC:0001493152-25-024875:0
Canonical exit: 19 Feb 2026 (T+90) ▲ Chief Executive Officer · Executives · 22 Aug 2025
5,000 shares @ US$0.9495 10.2% of flow Common Stock SEC:0001641172-25-025459:0
Canonical exit: 20 Nov 2025 (T+90) ▲ Chief Executive Officer · Executives · 25 Aug 2025
5,000 shares @ US$0.9098 9.8% of flow Common Stock SEC:0001641172-25-025459:1
Canonical exit: 23 Nov 2025 (T+90) ▲ Chief Medical Officer · Executives · 5 Jun 2025
21,000 shares @ US$1.40 27.3% of flow Common Stock SEC:0001641172-25-014212:0
Canonical exit: 3 Sept 2025 (T+90) ● Chief Medical Officer · Executives · 22 Apr 2025
400,000 shares 0Common Stock SEC:0001641172-25-014112:0
◇ Director · Executives · 2 May 2025
20,480 shares @ US$0.15 4.8% of flow Common Stock SEC:0001641172-25-008842:0
▲ Chief Medical Officer · Executives · 15 Apr 2025
15,000 shares @ US$0.90 17.5% of flow Common Stock SEC:0001641172-25-005139:0
Canonical exit: 14 Jul 2025 (T+90) ▲ Chief Executive Officer · Executives · 15 Apr 2025
7,500 shares @ US$0.9095 15.1% of flow Common Stock SEC:0001641172-25-004955:0
Canonical exit: 14 Jul 2025 (T+90) ▲ Chief Medical Officer · Executives · 11 Apr 2025
20,000 shares @ US$0.80 20.8% of flow Common Stock SEC:0001641172-25-003951:0
Canonical exit: 10 Jul 2025 (T+90) ▲ VP Controller and PAO · Executives · 8 Apr 2025
95 shares @ US$0.80 100.0% of flow Common Stock SEC:0001641172-25-003675:0
Canonical exit: 7 Jul 2025 (T+90) ▲ Chief Executive Officer · Executives · 9 Apr 2025
10,000 shares @ US$0.83 19.0% of flow Common Stock SEC:0001641172-25-003504:0
Canonical exit: 8 Jul 2025 (T+90) ▲ Chief Medical Officer · Executives · 9 Apr 2025
30,000 shares @ US$0.8133 32.6% of flow Common Stock SEC:0001641172-25-003631:0
Canonical exit: 8 Jul 2025 (T+90) ▲ Chief Medical Officer · Executives · 8 Apr 2025
26,000 shares @ US$0.84 29.1% of flow Common Stock SEC:0001641172-25-003364:0
Canonical exit: 7 Jul 2025 (T+90) 25 of 37 declarations
Load more (12 remaining) 关于 RenovoRx, Inc. RenovoRx, Inc. 是一家专注于开发癌症治疗靶向疗法的公司。它专注于局部药物递送以提高治疗效果。